Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Dario Kivelevitch, Bobbak Mansouri, Alan Menter Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA Abstract: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of...

Descripción completa

Guardado en:

Detalles Bibliográficos
Autores principales:	Kivelevitch D, Mansouri B, Menter A
Formato:	article
Lenguaje:	EN
Publicado:	Dove Medical Press 2014
Materias:	Medicine (General) R5-920
Acceso en línea:	https://doaj.org/article/63a0f93d1cc24c85982a4a82dc041e1a
Etiquetas:	Agregar Etiqueta Sin Etiquetas, Sea el primero en etiquetar este registro!

id	oai:doaj.org-article:63a0f93d1cc24c85982a4a82dc041e1a
record_format	dspace
spelling	oai:doaj.org-article:63a0f93d1cc24c85982a4a82dc041e1a2021-12-02T04:14:31ZLong term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis1177-5475https://doaj.org/article/63a0f93d1cc24c85982a4a82dc041e1a2014-04-01T00:00:00Zhttp://www.dovepress.com/long-term-efficacy-and-safety-of-etanercept-in-the-treatment-of-psoria-a16505https://doaj.org/toc/1177-5475 Dario Kivelevitch, Bobbak Mansouri, Alan Menter Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA Abstract: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis. Keywords: psoriasis, psoriatic arthritis, etanercept, biological therapy, tumor necrosis factor, safetyKivelevitch DMansouri BMenter ADove Medical PressarticleMedicine (General)R5-920ENBiologics: Targets & Therapy, Vol 2014, Iss default, Pp 169-182 (2014)
institution	DOAJ
collection	DOAJ
language	EN
topic	Medicine (General) R5-920
spellingShingle	Medicine (General) R5-920 Kivelevitch D Mansouri B Menter A Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
description	Dario Kivelevitch, Bobbak Mansouri, Alan Menter Department of Dermatology, Baylor University Medical Center, Dallas, TX, USA Abstract: Psoriasis is a chronic, immune-mediated inflammatory disease affecting both the skin and joints. Approximately 20% of patients suffer a moderate to severe form of skin disease and up to 30% have joint involvement. Standard therapies for psoriasis include topical medications, phototherapy, and both oral systemic and biological therapies whereas therapies for psoriatic arthritis include nonsteroidal anti-inflammatory drugs followed by disease modifying antirheumatic drugs and/or tumor necrosis factor (TNF)-α inhibitors and interleukin-12/23p40 inhibitors. Treatment of both diseases is typically driven by disease severity. In the past decade, major advances in the understanding of the immunopathogenesis of psoriasis and psoriatic arthritis have led to the development of numerous biological therapies, which have revolutionized the treatment for moderate to severe plaque psoriasis and psoriatic arthritis. Anti-TNF-α agents are currently considered as first line biological therapies for the treatment of moderate to severe psoriasis and psoriatic arthritis. Currently approved anti-TNF-α agents include etanercept, adalimumab, and infliximab for psoriasis and psoriatic arthritis as well as golimumab and certolizumab for psoriatic arthritis. In this article, we aim to evaluate the long term safety and efficacy of etanercept in psoriasis and psoriatic arthritis. Keywords: psoriasis, psoriatic arthritis, etanercept, biological therapy, tumor necrosis factor, safety
format	article
author	Kivelevitch D Mansouri B Menter A
author_facet	Kivelevitch D Mansouri B Menter A
author_sort	Kivelevitch D
title	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
title_short	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
title_full	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
title_fullStr	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
title_full_unstemmed	Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
title_sort	long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis
publisher	Dove Medical Press
publishDate	2014
url	https://doaj.org/article/63a0f93d1cc24c85982a4a82dc041e1a
work_keys_str_mv	AT kivelevitchd longtermefficacyandsafetyofetanerceptinthetreatmentofpsoriasisandpsoriaticarthritis AT mansourib longtermefficacyandsafetyofetanerceptinthetreatmentofpsoriasisandpsoriaticarthritis AT mentera longtermefficacyandsafetyofetanerceptinthetreatmentofpsoriasisandpsoriaticarthritis
_version_	1718401373674930176

Long term efficacy and safety of etanercept in the treatment of psoriasis and psoriatic arthritis

Ejemplares similares